Multiple RNA splicing and the presence of cryptic RNA splice donor and acceptor sites may contribute to low expression levels and poor immunogenicity of potential DNA vaccines containing the env gene of equine infectious anemia virus (EIAV).
The env gene is an excellent candidate for inclusion in any DNA-based vaccine approach against equine infectious anemia virus (EIAV). Unfortunately, this gene is subjected to mutational pressure in E. coli resulting in the introduction of stop codons at the 5' terminus unless it is molecularly cloned using very-low-copy-number plasmid vectors. To overcome this problem, a mammalian expression vector was constructed based on the low-copy-number pLG338-30 plasmid. This permitted the production of full-length EIAV env gene clones (plcnCMVenv) from which low-level expression of the viral surface unit glycoprotein (gp90) was detected following transfection into COS-1 cells. Although this suggested the nuclear export of complete env mRNA moieties at least two additional polypeptides of 29 and 20kDa (probably Rev) were produced by alternative splicing events as demonstrated by the fact that their synthesis was prevented by mutational inactivation of EIAV env splice donor 3 (SD3) site. The plcnCMVenv did not stimulate immune responses in mice or in horses, whereas an env construct containing an inactivated SD3 site (plcnCMVDeltaSD3) did induce weak humoral responses against gp90 in mice. This poor immunogenicty in vivo was probably not related to the inherent antigenicity of the proteins encoded by these constructs but to some fundamental properties of EIAV env gene expression. Attempts to modify one of these properties by mutational inactivation of known viral RNA splice sites resulted in activation of previously unidentified cryptic SD and slice acceptor sites.
Zhou
W
W
Department of Veterinary Science, University of Kentucky, Maxwell H. Gluck Equine Research Center, Lexington, KY 40546-0099, USA.
Cook
R F
RF
Cook
S J
SJ
Hammond
S A
SA
Rushlow
K
K
Ghabrial
N N
NN
Berger
S L
SL
Montelaro
R C
RC
Issel
C J
CJ
D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001483:Base Sequence; D003001:Cloning, Molecular / Q000379:methods; D018388:Codon, Terminator; D004859:Equine Infectious Anemia / Q000276:immunology / Q000517:prevention & control; D015967:Gene Expression Regulation, Viral; D015686:Gene Products, env / Q000235:genetics; D015752:Genes, env; D006736:Horses; D004860:Infectious Anemia Virus, Equine / Q000235:genetics* / Q000276:immunology; D051379:Mice; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D012326:RNA Splicing / Q000235:genetics*; D012367:RNA, Viral / Q000737:chemistry; D014162:Transfection / Q000662:veterinary; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D018388:Codon, Terminator; D015686:Gene Products, env; D012367:RNA, Viral; D019444:Vaccines, DNA; D014765:Viral Vaccines